Background: Canine obesity is a common disorder accompanied by a low-grade chronic inflammation and is considered a risk factor for liver and heart diseases. The present study aimed to investigate whether an olive oil-derivative enriched in N-acylethanolamines (Olaliamid, OLA) may protect dogs against obesity-induced comorbidities. Results: Twenty-seven dogs of mixed breed and size with a body condition score >= 7/9 were included in the trial, once provided they were otherwise healthy. Dogs were fed a commercial maintenance diet for two weeks before enrolment, and randomized in two groups, i.e., OLA (n = 14) and placebo (OLA vehicle; n = 13). Both treatments were administered orally by the owners in a liquid form at 0.7 ml/5kg body weight, once a day for three months. At baseline and three months later dogs underwent physical examination, blood draw, and echocardiography. At the same timepoints, owners were given a questionnaire about their dog's general condition. OLA prevented the increase in leptin observed in the placebo group (P = 0.011), decreased IL-6 (P = 0.043) and derivatives-reactive oxygen metabolites (d-ROMs, P = 0.008), and increased biological antioxidant potential (BAP) compared to the placebo group (P = 0.032). Moreover, OLA protected the liver, with ALT levels being decreased in the OLA group compared to the placebo one (P = 0.005) and bilirubin levels being decreased in the OLA group (P = 0.030) but not in the placebo one. OLA showed a cardioprotective effect, with a significant decrease of IVSdN (P = 0.028), LVPWdN (P = 0.047), IVSd/LVIDd (P = 0.015) and LVPWd/LVIDd (P = 0.034) compared to the placebo group. According to dog owners, the difficulty rising from lying down significantly increased in the placebo group (P = 0.039) but not in the OLA one. Conclusion: Overall, OLA improved obesity-induced meta-inflammation and oxidative status and helped to ameliorate liver and heart health as well.

An olive oil-derived NAE mixture (Olaliamid) improves liver and cardiovascular health, and decreases meta-inflammation in naturally obese dogs: a double-blind, randomized, placebo-controlled study / Piantedosi, D., Morelli, G., Musco, N., Schievano, C., Maria Federica Della, V., Pizzo, F., Nasir, S., Abate, G., Ferrara, M., Lombardi, P., Cortese, L.. - In: BMC VETERINARY RESEARCH. - ISSN 1746-6148. - 21:1(2025), pp. 1-17. [10.1186/s12917-025-04946-y]

An olive oil-derived NAE mixture (Olaliamid) improves liver and cardiovascular health, and decreases meta-inflammation in naturally obese dogs: a double-blind, randomized, placebo-controlled study

Piantedosi Diego
Primo
;
Musco Nadia
;
Pizzo Francesco;Nasir Saad;Abate Giulia;Ferrara Maria;Lombardi Pietro
Penultimo
;
Cortese Laura
2025

Abstract

Background: Canine obesity is a common disorder accompanied by a low-grade chronic inflammation and is considered a risk factor for liver and heart diseases. The present study aimed to investigate whether an olive oil-derivative enriched in N-acylethanolamines (Olaliamid, OLA) may protect dogs against obesity-induced comorbidities. Results: Twenty-seven dogs of mixed breed and size with a body condition score >= 7/9 were included in the trial, once provided they were otherwise healthy. Dogs were fed a commercial maintenance diet for two weeks before enrolment, and randomized in two groups, i.e., OLA (n = 14) and placebo (OLA vehicle; n = 13). Both treatments were administered orally by the owners in a liquid form at 0.7 ml/5kg body weight, once a day for three months. At baseline and three months later dogs underwent physical examination, blood draw, and echocardiography. At the same timepoints, owners were given a questionnaire about their dog's general condition. OLA prevented the increase in leptin observed in the placebo group (P = 0.011), decreased IL-6 (P = 0.043) and derivatives-reactive oxygen metabolites (d-ROMs, P = 0.008), and increased biological antioxidant potential (BAP) compared to the placebo group (P = 0.032). Moreover, OLA protected the liver, with ALT levels being decreased in the OLA group compared to the placebo one (P = 0.005) and bilirubin levels being decreased in the OLA group (P = 0.030) but not in the placebo one. OLA showed a cardioprotective effect, with a significant decrease of IVSdN (P = 0.028), LVPWdN (P = 0.047), IVSd/LVIDd (P = 0.015) and LVPWd/LVIDd (P = 0.034) compared to the placebo group. According to dog owners, the difficulty rising from lying down significantly increased in the placebo group (P = 0.039) but not in the OLA one. Conclusion: Overall, OLA improved obesity-induced meta-inflammation and oxidative status and helped to ameliorate liver and heart health as well.
2025
An olive oil-derived NAE mixture (Olaliamid) improves liver and cardiovascular health, and decreases meta-inflammation in naturally obese dogs: a double-blind, randomized, placebo-controlled study / Piantedosi, D., Morelli, G., Musco, N., Schievano, C., Maria Federica Della, V., Pizzo, F., Nasir, S., Abate, G., Ferrara, M., Lombardi, P., Cortese, L.. - In: BMC VETERINARY RESEARCH. - ISSN 1746-6148. - 21:1(2025), pp. 1-17. [10.1186/s12917-025-04946-y]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/1053895
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact